Intervention
Warfarin
ClinicalTrials.gov intervention label
How to interpret these research links
Connected source recordsThis is the original ClinicalTrials.gov intervention label, found in 40 distinct published trials. Registry interventions may represent drugs, devices, procedures or other study activities. A matched term or study association does not establish product equivalence, efficacy or regulatory approval.
Data basis: current published ClinicalTrials.gov records and, where present, RxNorm, MONDO and FDA-label identifiers. See the evidence interpretation and counting methodology.
Advertisement
Clinical trials
40 shownA Drug-Drug Interaction Study of HDM1002 and Metformin, Empagliflozin, Midazolam, Valsartan, and WarfarinNCT07331389 · 2025-09-24
RECRUITINGAspirin and Hemocompatibility Events in Chronic Advanced Heart Failure Patients With Assist DeviceNCT06655376 · 2024-10-02
RECRUITINGThe Danish Warfarin-Dialysis Study - Safety and Efficacy of Warfarin in Patients With Atrial Fibrillation on DialysisNCT03862859 · 2019-10-09
RECRUITINGSWITCH: Apixaban vs Vitamin K in HM3NCT07471139 · 2026-08-01
NOT_YET_RECRUITINGInfluence of HDM1005 on Gastric Emptying and Pharmacokinetics of Metformin, Atorvastatin, Warfarin, and DigoxinNCT07502001 · 2026-04-08
NOT_YET_RECRUITINGA Study of BGM0504 in Overweight or Obese ParticipantsNCT06920056 · 2025-03-24
COMPLETEDInfluence of HRS9531 on Gastric Emptying and Pharmacokinetics of Metformin, Atorvastatin, Warfarin, and Digoxin in Healthy SubjectsNCT06723691 · 2024-12-18
COMPLETEDA Study on How CagriSema Affects Levels of Atorvastatin and Warfarin in the Blood of Participants With Excess Body WeightNCT06289504 · 2024-02-27
COMPLETEDA Drug-Drug Interaction (DDI) Study of LY3437943 in Obese ParticipantsNCT05445232 · 2022-07-08
COMPLETEDEvaluation of the Hemocompatibility of the Direct Oral Anti-Coagulant Apixaban in Left Ventricular Assist DevicesNCT04865978 · 2021-12-14
COMPLETEDApixaban, Warfarin and Aspirin Prevents Portal Vein Thrombosis in Patients After Laparoscopic Splenectomy（ESAWAAPT）NCT04645550 · 2020-11-22
COMPLETEDA Study Using Electronic Health Information to Learn About Rivaroxaban Compared to Warfarin in Participants With Non-valvular Atrial Fibrillation (NVAF) and DiabetesNCT04509193 · 2020-08-21
COMPLETEDPROACT Xa - A Trial to Determine if Participants With an On-X Aortic Valve Can be Maintained Safely on ApixabanNCT04142658 · 2020-05-01
TERMINATEDStrategies for the Management of Atrial Fibrillation in patiEnts Receiving DialysisNCT03987711 · 2019-12-10
COMPLETEDAnti-thrombotic Monotherapy in HeartMate 3 Left Ventricular Assist System (LVAS)NCT03781258 · 2018-11-23
UNKNOWNAnti-thrombotic Monotherapy With the HeartMate 3 LVASNCT03704220 · 2018-08-16
UNKNOWNEffect of BIA 5-1058 400 mg on Warfarin PharmacokineticsNCT04994119 · 2018-02-23
COMPLETEDStudy to Compare Pharmacokinetics & Pharmacodynamics of Warfarin & Esmolol in the Absence & Presence of MEDI0382NCT03347968 · 2017-11-27
COMPLETEDThe Appropriate Anticoagulation Duration for Chronic Obstructive Pulmonary Disease With Pulmonary ThromboembolismNCT03185845 · 2017-06-15
UNKNOWNMAGENTUM 1 HeartMate 3 LVAS: A Single Center Prospective Controlled Study (MAGENTUM 1)NCT03078374 · 2017-01-11
UNKNOWNDirect Oral Anticoagulants (DOACs) Versus LMWH +/- Warfarin for VTE in CancerNCT02744092 · 2016-12-13
COMPLETEDPrevention of Non-Surgical Bleeding by Management of HeartMate II Patients Without Antiplatelet TherapyNCT02836652 · 2016-11-01
COMPLETEDORal anticoaGulants in diAbetic and Nondiabetic Patients With nOn-valvular Atrial fibrillatioN (ORGANON)NCT02935855 · 2015-09-01
COMPLETEDEvaluate the Pharmacokinetics of Warfarin When Coadministered With PEX168 in Healthy Adult SubjectsNCT02461914 · 2015-08-01
COMPLETEDWarfarin Prevents Portal Vein Thrombosis in Patients After Laparoscopic Splenectomy and Azygoportal DisconnectionNCT02247414 · 2014-09-01
COMPLETEDWarfarin Prevents Portal Vein Thrombosis in Liver Cirrhotic Patients With Hypersplenism After Laparoscopic SplenectomyNCT02238444 · 2014-09-01
UNKNOWNUse of Ventavis in Patients With Postembolic Residual Pulmonary HypertensionNCT02238535 · 2014-09-01
UNKNOWNEffect of Opicapone at Steady State on Warfarin PharmacokineticsNCT02305030 · 2014-03-01
COMPLETEDDrug-drug Interaction Study(Lobeglitazone, Warfarin)NCT02002611 · 2013-12-01
COMPLETEDA Study to Evaluate the Effect of a Single Dose of CNTO 136 (Sirukumab) on CYP450 Enzyme Activities After Subcutaneous Administration in Patients With Rheumatoid ArthritisNCT01636557 · 2012-10-11
COMPLETEDA Study of the Effect of Dulaglutide on the Action of Warfarin in Healthy ParticipantsNCT01432938 · 2011-09-01
COMPLETEDDrug-drug Interaction Study With MDV3100 and a Cocktail of SubstratesNCT01911728 · 2011-07-25
COMPLETEDA Study of LY2216684 and Warfarin in Healthy SubjectsNCT01263119 · 2010-12-01
COMPLETEDInvestigate the Effect of AZD1656 on the Pharmacokinetics and Pharmacodynamics of Warfarin in Type 2 Diabetes Mellitus (T2DM) PatientsNCT01103609 · 2010-04-01
COMPLETEDAnticoagulation For Pulmonary Hypertension in Sickle Cell DiseaseNCT01036802 · 2009-12-01
TERMINATEDStudy of the Effect of Dapagliflozin on the Pharmacokinetics of Warfarin or Digoxin in Healthy SubjectsNCT00904176 · 2009-06-01
COMPLETEDEffect of BIA 9-1067 on the Pharmacokinetics and Pharmacodynamics of WarfarinNCT02169440 · 2009-06-01
COMPLETEDA Phase 1, Randomized, Open-Label, Two-Way Crossover Study To Evaluate The Steady-State Effect Of Dimebon (PF 01913539) On The Single-Dose Pharmacokinetics And Pharmacodynamics Of Warfarin In Healthy SubjectsNCT00827034 · 2009-02-01
COMPLETEDDrug Interaction Study Between AZD3480 and WarfarinNCT00689637 · 2007-09-01
COMPLETEDWarfarin Versus Aspirin in Reduced Cardiac Ejection Fraction (WARCEF) TrialNCT00041938 · 2002-10-01
COMPLETEDCommon conditions
Heart Failure6Cardiovascular Diseases3Cirrhosis3Obesity3Stroke3Type 2 Diabetes Mellitus3Venous Thrombosis3Alzheimer's Disease2Atrial Fibrillation2Bleeding2Hypertension2Aortic Valve Disease1Aortic Valve Failure1Aortic Valve Stenosis1Arthritis, Rheumatoid1Atrial Fibrillation and Flutter1Blood Clot1Cancer1Castration Resistant Prostate Cancer (CRPC)1Clot Blood1COPD Exacerbation1Deep Vein Thrombosis (DVT)1Diabetes1Diabetes Mellitus, Type 21End Stage Renal Failure on Dialysis1
Mapped diseases appearing in these trials
Shared study participation does not establish that this intervention treats a disease.
heart failure6type 2 diabetes mellitus5cirrhosis of liver3obesity disorder3stroke disorder3Alzheimer disease2atrial fibrillation2aortic valve disorder1aortic valve stenosis1cancer1diabetes mellitus1end stage renal failure1heart disorder1Huntington disease1major depressive disorder1myocardial infarction1myocardial ischemia1Parkinson disease1portal hypertension1pulmonary arterial hypertension1
Leading sponsors
AstraZeneca
3
Bial - Portela C S.A.
3
Columbia University
3
Eli Lilly and Company
3
Institute for Clinical and Experimental Medicine
3
Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.
2
Yangzhou University
2
Abbott Medical Devices
1
Alliance Foundation Trials, LLC.
1
Artivion Inc.
1
Astellas Pharma Europe B.V.
1
Bayer
1
BrightGene Bio-Medical Technology Co., Ltd.
1
Chinese Academy of Medical Sciences, Fuwai Hospital
1
Chong Kun Dang Pharmaceutical
1
Trial status mix
COMPLETED27
UNKNOWN6
RECRUITING3
NOT_YET_RECRUITING2
TERMINATED2
Phase mix
PHASE120
PHASE47
NA5
PHASE24
PHASE33
Advertisement
Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.